Proteon founders launch new company Novita
This article was originally published in Scrip
The founders of Proteon Therapeutics have launched a new venture, Novita Therapeutics, and closed a first round of financing from angel investors. The new firm will focus on biopharmaceuticals and medical devices to treat cardiovascular, renal and gastrointestinal diseases.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.